3 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Withdrawn 3 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Atrophy: new trials by email Literature Review of Atrophy trials Research Report on Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial OLIMEL 7,6%E / PeriOLIMEL 2,5%E - Nutritional Disorder, Critical Illness | Phase 3 | Withdrawn | RWTH Aachen University | 2020-06-01 | 2022-10-27 | |
| Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit beta-hydroxy-beta-methylbutyrate, Placebo, Vital HP® - Muscle Atrophy | Phase 2 / Phase 3 | Withdrawn | Massachusetts General Hospital | 2017-01-01 | 2021-05-05 |
Critical Illness (2) · Muscular Atrophy (2) · Frailty (1) · Malnutrition (1) · Mitochondrial Diseases (1) · Muscle Weakness (1) · Nutrition Disorders (1) · Sarcopenia (1)
Nervous System Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Manifestations (3) · Pathologic Processes (3) · Pathological Conditions, Anatomical (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Disease Attributes (2) · Nutritional and Metabolic Diseases (2) · Metabolic Diseases (1) · Muscular Atrophy (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1)
Deoxycytidine (1) · Thymidine (1) · beta-hydroxyisovaleric acid (1)
Massachusetts General Hospital (1) · RWTH Aachen University (1) · Zogenix MDS, Inc. (1)
Germany (1)
Christian Stoppe, MD (1) · Sadeq A. Quraishi, MD,MHA,MMSc (1)